NCT00419081

Phase 2Interventional

Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.

View on ClinicalTrials.gov ↗

Timeline

Start date: Jul 1, 2006
Primary completion: Mar 1, 2007
Completion date: Mar 1, 2007
First posted: —
Last posted: —
Enrollment: 100
Arms / groups: — / —
Source: AACT · pre-existing

Sponsors

BioCrystLead sponsor
Technical University of DresdenOverall official - principal investigator
Faculdade de Medicina do ABCOverall official - principal investigator
University of FloridaOverall official - principal investigator
University of California, Los AngelesOverall official - principal investigator
Federal University of Rio Grande do SulOverall official - principal investigator
University of Texas at HoustonOverall official - principal investigator
Cornell UniversityOverall official - principal investigator
Hospital Nossa Senhora da ConceicaoOverall official - principal investigator
University of Sao PauloOverall official - principal investigator
Centro Goiano de OncologiaOverall official - principal investigator
Fundacao Hospital Amaral CarvalhoOverall official - principal investigator
Hospital BrigadeiroOverall official - principal investigator
Instituto de Oncologia Pediatrica - GRAACC Grupo de Apoio as Adolescente e a Crianca com Cancer - UNIFESPOverall official - principal investigator
Free State UniversityOverall official - principal investigator
Liberty Hematology and OncologyOverall official - principal investigator
Service Clinique des Maladies du SangOverall official - principal investigator
Istitutp di Ematologia ed Oncologia MedicaOverall official - principal investigator
Azienda Ospedaliera Antonio CardarelliOverall official - principal investigator
Vanderbilt UniversityOverall official - principal investigator
University of ChicagoOverall official - principal investigator
Azienda Osperdaliera Vincenzo Cervello DivisioneOverall official - principal investigator
Complessa di Ematologia and Dir DepartmentoOverall official - principal investigator
Hospital de Clinicias da UICAMPOverall official - principal investigator
Universidade Federal do ParanaOverall official - principal investigator
Hospital Santa Marcelina, Sao Paulo, BrasilOverall official - principal investigator
Klinika OkulistykiOverall official - principal investigator
University of DuesseldorfOverall official - principal investigator
University of FlorenceOverall official - principal investigator
CHU Hart LevequeOverall official - principal investigator
University of PalermoOverall official - principal investigator
New York Medical CollegeOverall official - principal investigator
Tufts UniversityOverall official - principal investigator
Government of BrazilOverall official - principal investigator
Hospital Erasto GaertnerOverall official - principal investigator
Emory UniversityOverall official - principal investigator
Instituto Estadual de Hematologia Arthur de Siqueira CavalcantiOverall official - principal investigator
State University of New York, BuffaloOverall official - principal investigator
University of Alabama, BirminghamOverall official - principal investigator
Icahn School of Medicine at Mount SinaiOverall official - principal investigator
Erasmus University RotterdamOverall official - principal investigator
Louisiana State UniversityOverall official - principal investigator
University of RegensburgOverall official - principal investigator
Humboldt UniversityOverall official - principal investigator
University of RochesterOverall official - principal investigator

Drugs studied

forodesine

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.